查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992820

干眼症治疗市场：2026-2030年全球市场预测（按剂型、药物类型、治疗类型、最终用户、治疗持续时间和分销管道划分）

Dry Eye Medication Market by Product Form, Drug Type, Medication Type, End-user, Treatment Duration, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年干眼症治疗市场价值为 51.6 亿美元，预计到 2025 年将成长至 54.9 亿美元，复合年增长率为 6.72%，到 2030 年将达到 76.2 亿美元。

主要市场统计数据
基准年 2024 51.6亿美元
预计年份：2025年 54.9亿美元
预测年份 2030 76.2亿美元
复合年增长率 (%) 6.72%

为全面概述干眼症治疗奠定基础，重点在于患者需求、技术进步和监管趋势。

近年来，受电子萤幕使用增加、环境压力以及全球人口老化等因素的影响，干眼症的盛行率急剧上升。随着患者越来越寻求缓解眼睛不适的方法，干眼症治疗市场已成为製药创新和医疗保健投资的重点。本文首先概述了干眼症的潜在风险因素，然后介绍了当前的市场格局，并揭示了从睑板腺功能障碍到泪膜不稳定等多种病因如何推动临床和商业性需求。

前所未有的创新和数位融合正在推动干眼症治疗方案和市场发展的新浪潮。

干眼症治疗市场正经历着变革性的转变，治疗模式和市场结构正在重塑。新型药物递送平台，例如微乳剂眼药水和缓释型眼内植入物，无需频繁用药即可提供持续缓解，从而显着提高了患者的依从性。同时，从智慧型手机泪液分析仪到远端监测平台等数位健康工具的整合，使得即时收集患者数据成为可能，有助于制定更个人化的治疗方案。

评估 2025 年美国关税对干眼症治疗供应链、製造成本和全球贸易趋势的连锁反应。

2025年，美国新关税的实施给干眼症药物的整个供应链带来了巨大的成本压力。关键药用辅料和包装材料的关税提高了生产成本，迫使企业重新评估筹资策略，并与替代供应商谈判合约。因此，契约製造生产商（CMO）的利润率面临压力，这可能导致下游市场的价格调整。这可能会影响病人的用药和医保报销谈判。

为了有策略地分配资源，我们深入研究了各种细分方面，揭示了治疗方法的细微差异。

对市场细分的详细分析揭示了患者和产品属性的差异如何影响策略重点。虽然眼药水等製剂仍然是治疗方案的基础，但眼睑擦拭巾和眼膏等新型产品正在满足特定需求，尤其适用于需要在睡眠期间局部缓解症状或进行眼表清洁的患者。儘管凝胶和喷雾剂占据的市场份额较小，但它们为那些无法耐受传统眼药水或需要快速缓解症状的患者提供了替代方案。

区域比较分析揭示了美洲、欧洲、中东和非洲以及亚太市场的明确驱动因素、机会和挑战。

区域趋势对市场发展有显着影响，每个地区在监管、经济和患者群体方面都有其独特的考量。在美洲，成熟的医疗基础设施和健全的报销体系支持高品质製剂和创新给药系统的快速普及。临床医生和患者的高度认知推动了对先进治疗方法的需求，而支付方则重视已证实的临床效益和成本效益。

揭示定义干眼症治疗市场竞争领导地位的创新伙伴关係、产品线策略和永续发展倡议。

干眼症治疗领域的主要企业正透过策略性投资研发、全球扩张计画和产品组合多元化来提升自身竞争力。一些产业先驱优先透过收购利基生物技术创新企业来丰富产品线，从而获得独特的免疫调节分子和先进的药物递送平台。另一些企业则在加强与合约研究组织（CRO）的合作，以加速临床开发并优化资本配置。

干眼症治疗公司在推动创新方面面临的策略挑战：加强病人参与和确保供应链的韧性。

行业领导企业应优先考虑对下一代药物输送系统和新型治疗方法进行有针对性的研发投资，以满足不断变化的患者期​​望和保险报销标准。透过推进与数位医疗的整合，例如利用远端医疗平台进行居家泪膜评估和药物依从性追踪，企业可以实现产品差异化，并进一步提升患者参与度。

结合定性专业知识和定量检验的综合调查方法框架，用于干眼症市场分析。

这项市场调查基于严谨且多维度的调查方法，旨在确保分析的深度和可靠性。主要研究工作包括对关键意见领袖（KOL）进行深入访谈，访谈对象包括眼科医生、验光师和医药经济学专家，从而获得关于临床应用和报销框架的真实观点。此外，与产业主管的直接咨询也让我们深入了解了他们的策略重点、产品平臺和合作趋势。

整合以创新、细分趋势和区域差异为重点的关键研究成果，以指导未来的策略决策。

不断发展的干眼症治疗市场呈现出技术创新、监管环境变化和患者细分日益精细化的融合趋势。先进配方和数位健康工具的引入有望重新定义治疗标准，而关税驱动的供应链调整则凸显了营运灵活性的重要性。从地理来看，市场成熟度因地区而异，从美洲高度发展的医保体系，到亚太地区对成本高度敏感的成长型市场，再到欧洲、中东和非洲地区（EMEA）复杂的监管环境，不一而足。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 干眼症治疗市场：依产品形式划分

  • 眼药水
  • 眼睑湿纸巾
  • 凝胶/软膏
  • 喷

第九章：干眼症治疗药物市场

  • 非处方药
  • 处方药

第十章：干眼症治疗药物市场

  • 抗发炎药
  • 人工泪液
  • 免疫调节剂
  • 脂质疗法

第十一章 干眼症治疗市场：依最终使用者划分

  • 成人
  • 老年人
  • 儿童

第十二章：依治疗时间分類的干眼症治疗市场

  • 长期
  • 短期

第十三章：干眼症治疗市场：依通路划分

  • 离线
    • 医院和诊所
    • 零售药房
    • 专科诊所
  • 在线的

第十四章 干眼症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 干眼症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 干眼症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国干眼症治疗市场

第十八章：中国干眼症治疗市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Harrow Health, Inc.
  • Johnson & Johnson Services, Inc.
  • Kiora Pharmaceuticals, Inc.
  • Laboratorios Sophia SA De CV
  • Nicox SA
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Wockhardt Ltd.
Product Code: MRR-1A1A064C0036

The Dry Eye Medication Market was valued at USD 5.16 billion in 2024 and is projected to grow to USD 5.49 billion in 2025, with a CAGR of 6.72%, reaching USD 7.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.16 billion
Estimated Year [2025] USD 5.49 billion
Forecast Year [2030] USD 7.62 billion
CAGR (%) 6.72%

Setting the Stage for a Comprehensive Dry Eye Medication Overview Highlighting Patient Needs Technological Advances and Regulatory Dynamics

The prevalence of dry eye disease has surged in recent years, propelled by increased digital screen usage, environmental stressors, and an aging global population. As patients increasingly seek relief from ocular discomfort, the dry eye medication landscape has become a focal point for pharmaceutical innovation and healthcare investment. Beginning with a broad understanding of underlying risk factors, this introduction maps out the current ecosystem, highlighting how multifactorial etiologies-from meibomian gland dysfunction to tear film instability-drive both clinical and commercial imperatives.

Moreover, emerging regulatory standards and patient expectations are reshaping product development priorities. With regulatory bodies emphasizing safety, efficacy, and patient-centric outcomes, manufacturers are navigating a complex framework that balances innovation with compliance. At the same time, healthcare providers are adopting minimally invasive treatment protocols, while payers demand evidence of cost-effectiveness and quality-of-life improvements. Against this backdrop, stakeholders must align strategic objectives with patient needs, ensuring that portfolios address acute symptoms and long-term ocular surface health.

In sum, this introduction sets the stage for a deeper exploration of market forces, technological breakthroughs, and policy dynamics that collectively influence the trajectory of dry eye therapies. It underscores the importance of a holistic perspective-one that integrates clinical science, commercial strategy, and patient experience-to capitalize on growth opportunities in a rapidly evolving arena.

Unprecedented Innovations and Digital Integration Driving the Next Wave of Dry Eye Therapeutic Solutions and Market Evolution

The dry eye medication landscape is witnessing transformative shifts that redefine therapeutic paradigms and market structures. Novel drug delivery platforms, such as microemulsion-based eye drops and sustained-release ocular inserts, are revolutionizing patient adherence by offering extended relief without frequent administration. Concurrently, the integration of digital health tools-ranging from smartphone-based tear film analyzers to remote monitoring platforms-enables real-time patient data collection, fostering more personalized treatment regimens.

At the same time, advancements in immunomodulatory agents are unlocking new pathways for chronic inflammation management, while lipid-based therapies are gaining traction for their capacity to restore tear film integrity. These innovations are complemented by a growing emphasis on preservative-free formulations, addressing safety concerns tied to long-term ocular surface exposure. In parallel, strategic collaborations between biotech firms and academic institutions are accelerating the translation of cutting-edge research into market-ready assets.

Meanwhile, evolving reimbursement frameworks are prompting manufacturers to demonstrate robust clinical and economic benefits, thereby influencing development timelines and go-to-market tactics. As a result, stakeholders are prioritizing real-world evidence generation and value-based contracting to secure favorable coverage decisions. Taken together, these converging forces herald a new era of patient-centric, data-driven dry eye therapeutics that promise enhanced efficacy, safety, and accessibility.

Assessing the Ripple Effects of 2025 United States Tariffs on Dry Eye Medication Supply Chains Manufacturing Costs and Global Trade Dynamics

In 2025, the implementation of new United States tariffs has introduced significant cost pressures across the dry eye medication supply chain. Tariffs on key pharmaceutical excipients and packaging materials have elevated manufacturing expenses, compelling companies to reassess sourcing strategies and negotiate alternative supplier agreements. Consequently, contract manufacturers are experiencing margin squeezes, leading to potential price adjustments downstream that may affect patient access and reimbursement negotiations.

In response, some firms are relocating production to tariff-exempt regions or investing in vertical integration to mitigate external cost volatility. These strategic shifts are accompanied by intensified risk management protocols, including dual-sourcing policies and inventory buffering, to ensure product availability amid fluctuating trade dynamics. Moreover, regulatory filings are now incorporating tariff impact assessments, reflecting a more comprehensive approach to product cost modeling.

As trade tensions evolve, market participants are also exploring local manufacturing incentives and government partnerships aimed at enhancing domestic production capacity. While such initiatives may bolster supply resilience, they require significant capital outlays and lead times. Ultimately, understanding the cumulative effects of tariff-related disruptions is critical for stakeholders intent on balancing cost containment, supply continuity, and patient affordability in a highly competitive marketplace.

Deep Dive into Diverse Segmentation Dimensions Illuminating Treatment Modalities Demographics and Distribution Nuances for Strategic Resource Allocation

A nuanced examination of market segmentation reveals how different patient and product attributes shape strategic priorities. Formulations such as eye drops remain the cornerstone of treatment regimens, but emerging options like eyelid wipes and ointments cater to specialized patient needs, particularly those requiring targeted relief during sleep or for ocular surface hygiene. Gels and sprays, though niche, offer alternatives for individuals intolerant to conventional drop instillation or seeking rapid symptomatic relief.

Diverging between over-the-counter availability and prescription-only therapies, manufacturers must tailor their promotional and distribution strategies accordingly. While artificial tears and anti-inflammatory medications dominate the retail shelf, immunomodulatory agents and lipid-based therapies occupy prescription channels, reflecting higher clinical complexity and oversight. Furthermore, the age-based segmentation of adults, geriatrics, and pediatrics underscores varying compliance challenges and dosing considerations, demanding bespoke educational and packaging features.

Treatment duration further refines the marketplace, with short-term interventions addressing acute flare-ups and long-term regimens focusing on chronic management. Finally, distribution channels-from hospital clinics and specialty centers to retail pharmacies and digital storefronts-determine outreach effectiveness and patient convenience. Offline channels benefit from clinical endorsements, whereas online platforms excel in convenience and broader geographic reach. Collectively, these segmentation dimensions illuminate nuanced growth pockets and inform targeted resource allocation across the product lifecycle.

Comparative Regional Analysis Revealing Distinct Drivers Opportunities and Challenges Spanning Americas EMEA and Asia Pacific Markets

Regional dynamics exert a profound influence on market trajectories, with each geography presenting distinct regulatory, economic, and patient profile considerations. In the Americas, mature healthcare infrastructure and robust reimbursement mechanisms support rapid adoption of premium formulations and innovative delivery systems. High awareness levels among clinicians and patients drive demand for advanced therapies, while payer frameworks reward demonstrable clinical benefits and cost-offsets.

Conversely, the Europe, Middle East & Africa region exhibits heterogeneity in regulatory pathways and economic maturity. Western European markets emphasize stringent safety and real-world evidence requirements, whereas emerging markets in the Middle East and Africa prioritize affordability and access. Navigating variable import regulations and localized pricing controls remains a key strategic focus, as does forging partnerships with regional distributors to streamline market entry.

In Asia-Pacific, rising dry eye prevalence is fueled by urbanization, pollution, and digital device proliferation. While developed markets like Japan and Australia show eagerness for next-generation therapies, cost-sensitive markets in Southeast Asia necessitate tiered pricing models and localized manufacturing alliances. Digital health adoption, particularly tele-ophthalmology platforms, is accelerating in populous markets, offering novel avenues for patient engagement and post-market support. These regional insights underscore the necessity of differentiated market strategies aligned with local healthcare dynamics.

Unveiling Innovative Partnerships Pipeline Strategies and Sustainability Initiatives Defining Competitive Leadership in Dry Eye Therapeutics

Leading companies in the dry eye medication arena are distinguished by their strategic investment in R&D, global expansion plans, and portfolio diversification. Some industry frontrunners have prioritized pipeline enrichment through acquisitions of niche biotech innovators, gaining access to proprietary immunomodulatory molecules and advanced drug delivery platforms. Others have cemented alliances with contract research organizations to expedite clinical development while optimizing capital deployment.

Simultaneously, partnerships with digital health startups are enabling select players to integrate remote monitoring solutions and personalized dosing algorithms into their offerings. Geographic expansion remains a critical theme, with firms establishing regional hubs to navigate local regulatory landscapes and bolster distribution networks. Collaboration with specialist eye clinics and ophthalmology societies further amplifies thought leadership and accelerates market penetration for cutting-edge therapies.

Furthermore, companies are increasingly focusing on sustainability and corporate responsibility, implementing eco-friendly packaging and reducing carbon footprints across manufacturing operations. Such initiatives not only resonate with stakeholder expectations but also align with emerging regulatory mandates. Overall, the competitive landscape is characterized by dynamic collaborations, technological convergence, and a relentless drive to deliver differentiated patient value.

Strategic Imperatives for Dry Eye Medication Companies to Drive Innovation Enhance Patient Engagement and Ensure Supply Chain Resilience

Industry leaders should prioritize targeted R&D investments in next-generation drug delivery systems and novel therapeutic modalities to meet evolving patient expectations and reimbursement criteria. Embracing digital health integration, including telemedicine platforms for home-based tear film assessments and adherence tracking, will differentiate offerings and foster stronger patient engagement.

Simultaneously, firms must fortify supply chain resilience by diversifying supplier portfolios and exploring localized manufacturing partnerships to mitigate tariff-induced cost fluctuations. Cultivating collaborative relationships with healthcare providers and payers through value-based contracting will support favorable formulary positioning and secure long-term revenue streams.

Moreover, adopting flexible pricing models that reflect regional economic conditions and patient affordability can unlock underserved markets, particularly in Asia-Pacific and parts of EMEA. Companies should also enhance educational outreach, leveraging digital channels and patient-support programs to elevate disease awareness and drive early intervention. By aligning product innovation, market access strategies, and operational agility, industry leaders can capitalize on emerging opportunities while mitigating potential risks in a competitive and regulatory-intensive environment.

Comprehensive Methodological Framework Integrating Qualitative Expertise and Quantitative Validation for Dry Eye Market Analysis

This market study is founded on a rigorous, multi-pronged research methodology designed to ensure analytical depth and reliability. Primary research efforts included in-depth interviews with key opinion leaders spanning ophthalmologists, optometrists, and pharmacoeconomics experts, providing real-world perspectives on clinical usage and reimbursement frameworks. Additionally, direct consultations with industry executives yielded insights into strategic priorities, product pipelines, and partnership trends.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, company annual reports, and industry white papers. Data triangulation techniques were employed to reconcile divergent information sources, while advanced statistical tools facilitated validation of qualitative findings against quantitative datasets. Segment-specific analyses were conducted via cross-tabulation of product form, drug type, medication classification, end-user demographics, treatment duration, and distribution channel variables.

Furthermore, region-specific regulatory and tariff impact assessments were integrated to contextualize market dynamics across the Americas, EMEA, and Asia-Pacific. All research outputs underwent rigorous peer review to ensure consistency, accuracy, and adherence to ethical research standards. This comprehensive approach underpins the study's actionable insights and strategic recommendations.

Synthesis of Core Findings Emphasizing Innovation Segmentation Dynamics and Regional Variances Guiding Future Strategic Decisions

The evolving dry eye medication market is characterized by a convergence of technological innovation, shifting regulatory landscapes, and nuanced patient segmentation. The introduction of advanced formulations and digital health tools promises to redefine therapeutic standards, while tariff-induced supply chain adjustments underscore the importance of operational agility. Regionally, market maturity varies from highly developed reimbursement systems in the Americas to cost-sensitive growth arenas in Asia-Pacific and regulatory complexities across EMEA.

Strategic segmentation analysis highlights the critical balance between over-the-counter accessibility and prescription-grade efficacy, as well as the imperative for tailored approaches across diverse age groups and treatment durations. Competitive dynamics are increasingly shaped by mergers and acquisitions, digital partnerships, and sustainability initiatives, reflecting a holistic value proposition that extends beyond pharmacology.

In conclusion, stakeholders that align their strategic investments with emerging trends-prioritizing innovation, patient-centricity, and supply chain resilience-will be best positioned to capture value in this rapidly transforming landscape. The insights offered herein provide a foundation for informed decision-making and long-term competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dry Eye Medication Market, by Product Form

  • 8.1. Eye Drops
  • 8.2. Eyelid Wipes
  • 8.3. Gels & Ointments
  • 8.4. Sprays

9. Dry Eye Medication Market, by Drug Type

  • 9.1. Over-The-Counter Medication
  • 9.2. Prescription Medication

10. Dry Eye Medication Market, by Medication Type

  • 10.1. Anti-inflammatory Medications
  • 10.2. Artificial Tears
  • 10.3. Immunomodulatory Agents
  • 10.4. Lipids-Based Therapy

11. Dry Eye Medication Market, by End-user

  • 11.1. Adults
  • 11.2. Geriatrics
  • 11.3. Pediatrics

12. Dry Eye Medication Market, by Treatment Duration

  • 12.1. Long Term
  • 12.2. Short Term

13. Dry Eye Medication Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Hospitals & Clinics
    • 13.1.2. Retail Pharmacies
    • 13.1.3. Specialty Clinics
  • 13.2. Online

14. Dry Eye Medication Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dry Eye Medication Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dry Eye Medication Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dry Eye Medication Market

18. China Dry Eye Medication Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Alcon Inc.
  • 19.7. Bausch + Lomb Corporation
  • 19.8. Harrow Health, Inc.
  • 19.9. Johnson & Johnson Services, Inc.
  • 19.10. Kiora Pharmaceuticals, Inc.
  • 19.11. Laboratorios Sophia S.A. De C.V.
  • 19.12. Nicox S.A.
  • 19.13. Ocugen, Inc.
  • 19.14. Ocular Therapeutix, Inc.
  • 19.15. Otsuka Pharmaceutical Co., Ltd.
  • 19.16. Santen Pharmaceutical Co., Ltd.
  • 19.17. Viatris Inc.
  • 19.18. Wockhardt Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 78. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 80. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. NORTH AMERICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 86. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 88. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 92. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. LATIN AMERICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 110. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 112. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 116. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. MIDDLE EAST DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 120. AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 124. AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. ASEAN DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. ASEAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 137. ASEAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ASEAN DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ASEAN DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. ASEAN DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 141. ASEAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. ASEAN DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 143. GCC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. GCC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 145. GCC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GCC DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. GCC DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. GCC DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 149. GCC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GCC DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPEAN UNION DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. BRICS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. BRICS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 161. BRICS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. BRICS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. BRICS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. BRICS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 165. BRICS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. BRICS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 167. G7 DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. G7 DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 169. G7 DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. G7 DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. G7 DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. G7 DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 173. G7 DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. G7 DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. NATO DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 176. NATO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 177. NATO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NATO DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NATO DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NATO DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 181. NATO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NATO DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 183. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)